Ionis Pharmaceuticals (IONS) Interest & Investment Income (2009 - 2026)

Ionis Pharmaceuticals' Interest & Investment Income history runs 18 years deep, the most recent figure standing at $25.5 million for Q1 2026.

• In Q1 2026, Interest & Investment Income rose 3.31% year-over-year to $25.5 million; the TTM figure through Mar 2026 stood at $98.6 million (down 6.47% YoY), while the FY2025 annual figure was $97.8 million, down 8.65% from the prior year.
• Interest & Investment Income was $25.5 million for Q1 2026 at Ionis Pharmaceuticals, up from $24.7 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $28.9 million in Q4 2024 to a low of $2.0 million in Q1 2022.
• Historically, Interest & Investment Income has averaged $20.2 million across 5 years, with a median of $24.7 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Interest & Investment Income slumped 57.08% in 2022, then soared 834.62% in 2023.
• A 5-year view of Interest & Investment Income shows it stood at $11.9 million in 2022, then soared by 116.14% to $25.7 million in 2023, then advanced by 12.55% to $28.9 million in 2024, then fell by 14.46% to $24.7 million in 2025, then increased by 3.05% to $25.5 million in 2026.
• The last three Interest & Investment Income figures came in at $25.5 million (Q1 2026), $24.7 million (Q4 2025), and $23.7 million (Q3 2025), per Business Quant data.